New anticoagulants: Anti IIa vs anti Xa - Is one better?

Journal of Thrombosis and Thrombolysis

Volumn 21, Issue 1, 2006, Pages 67-72

  Bauer, Kenneth A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

Anticoagulants; Factor Xa; Thrombin; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; ARGATROBAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DABIGATRAN ETEXILATE; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; LY 517717; MELAGATRAN; PLACEBO; PRODRUG; PROTHROMBIN INHIBITOR; RIVAROXABAN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; META ANALYSIS; PRIORITY JOURNAL; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; ENZYME INHIBITORS; FACTOR XA; HUMANS; RANDOMIZED CONTROLLED TRIALS; THROMBIN; THROMBOEMBOLISM;

EID: 32544453399     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-006-5579-4     Document Type: Article

References (16)

1. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran and warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703-1712.
2. Colwell CW, Berkowitz SD, Lieberman JR, et al. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am 2005;87:2169-2177.
3. Feissinger J-N, Huisman MV, Davidson BL, et al for the THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: A randomized trial. JAMA 2005;293:681-689.
4. Schulman S, Wählander K, Lundström, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-1721.
5. Weitz JI, Hirsh J, Samama MM. New anticoagulant drugs. The Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2004;126(Suppl):265S-286S.
6. Petitou M, Lormeau JC, Choay J. Chemical synthesis of glycosaminoglycans: New approaches to antithrombotic drugs. Nature. 1991;350(Suppl):30-33.
7. Herbert JM, Petitou M, Lormeau JC, et al. SR 90107/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 1997;15:1-26.
8. Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: A randomised double-blind comparison. Lancet. 2002;359:1715-1720.
9. Turpie AGG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: A randomised double-blind trial. Lancet 2002;359:1721-1726.
10. Bauer KA, Eriksson BI, Lassen MR, et al: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-1310.
11. Eriksson BI, Bauer KA, Lassen MR, et al: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;345:1298-1304.
12. Turpie AGG, Bauer KA, Eriksson BI, et al. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 randomized studies. Arch Intern Med 2002;162;1833-1840.
13. Eriksson BI, Lassen MR. Duration of Prophylaxis against thromboembolism with fondaparinux after hip fracture surgery: A mulicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003;163:1337-1342.
14. Agnelli G, Bergqvist D, Cohen AT, et al., on behalf of the PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surgery 2005;92:1212-1226.
15. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: A randomized trial. Ann Intern Med 2004;140:867-873.
16. The Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349:1695-1702.